Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
F. Hoffmann-La Roche AG currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner in 1 distinct art unit. This arrangement indicates a very specific and localized prosecution effort, with no other pending actions currently distributed across the patent office.
The busiest examiner for this portfolio is CHERNYSHEV, OLGA N, who is responsible for the 1 pending office action. As there is only 1 distinct examiner and 1 distinct art unit involved, the company's current prosecution strategy is focused on the feedback and requirements of CHERNYSHEV, OLGA N. This focus within the Biotechnology & Pharmaceuticals sector allows for a concentrated response to the 1 pending office action.
With 1 pending office action assigned to 1 distinct examiner, the administrative overhead for F. Hoffmann-La Roche AG is minimal. CHERNYSHEV, OLGA N, as the busiest examiner with 1 pending action, is the sole point of contact for the company's current pending matters. This profile, defined by 1 distinct art unit and 1 pending office action, reflects a streamlined approach to patent prosecution at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017951 | PREFILLED SYRINGE FORMULATION WITH NEEDLE WITH NEEDLE SHIELD CONTAINING NOVEL MODIFIED ANTIBODY | CHERNYSHEV, OLGA N | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18017951 | PREFILLED SYRINGE FORMULATION WITH NEEDLE WITH NEEDLE SHIELD CONTAINING NOVEL MODIFIED ANTIBODY | CHERNYSHEV, OLGA N | 1675 | §112 | Non-Final OA | — | Pending | Jul 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial